48 related articles for article (PubMed ID: 36377026)
1. Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab.
LaMorte D; Desmond D; Ellis J; Lipkowitz S
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479891
[TBL] [Abstract][Full Text] [Related]
2. RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Bertucci F; de Nonneville A; Finetti P; Mamessier E
J Natl Cancer Inst; 2023 Jun; 115(6):762-763. PubMed ID: 37004188
[No Abstract] [Full Text] [Related]
3. Three-year remission of metastatic breast cancer with treatment with ado-trastuzumab emtansine.
Caramujo C; Reis SN; Garcia AR; Sousa G
BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37879711
[TBL] [Abstract][Full Text] [Related]
4. Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis.
Dhamne N; Koyyala VPB; Chougule S; Pawar S
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35641086
[TBL] [Abstract][Full Text] [Related]
5. Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 May; 26(1):83. PubMed ID: 38790033
[No Abstract] [Full Text] [Related]
6. Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.
Haslem DS; Ji HP; Ford JM; Nadauld LD
JCO Precis Oncol; 2017; 1():. PubMed ID: 32913966
[No Abstract] [Full Text] [Related]
7. HER destiny too.
Higa GM
Transl Cancer Res; 2023 Nov; 12(11):2979-2983. PubMed ID: 38130308
[No Abstract] [Full Text] [Related]
8. More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.
Badulescu F; Badulescu A; Paul D; Popescu CF; Florescu C
Onco Targets Ther; 2014; 7():1911-7. PubMed ID: 25378932
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
10. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
11. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
Karacin C; Bilgetekin I; Basal FB; Oksuzoglu OB
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1501-1502. PubMed ID: 36377026
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
14. Ado-trastuzumab emtansine associated spider telangiectasia.
Gursoy P; Acar A; Acikalin T
J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
